Documents | Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | Guidance

A list of downloadable documents created during development.

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document information
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
Renal cell carcinoma - sunitinib: assessment report 12 October 2009 1.82 MB
Overview 07 August 2008 352.75 KB
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: consultee and commentator comments on the assessment report
Bayer 07 August 2008 12.94 KB
Kidney Research UK 07 August 2008 27.45 KB
NHS Quality Improvement Scotland 07 August 2008 17.41 KB
Pfizer 07 August 2008 46.16 KB
Pfizer 1 07 August 2008 128.35 KB
Pfizer 2 07 August 2008 418.47 KB
Roche 07 August 2008 109.71 KB
Royal College of Nursing 07 August 2008 20.98 KB
Royal College of Physicians 07 August 2008 47.7 KB
Wyeth 07 August 2008 182.88 KB
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: non-manufacturer submission
Cancer Backup 07 August 2008 50.34 KB
National Kidney Federation 07 August 2008 98.67 KB
Joint submission from Kidney Cancer UK and James Whale Fund for Kidney Cancer 07 August 2008 47.81 KB
Joint submission from NCRI Renal Clinical Studies Group/Royal College of Radiologists/Royal College of Physicians/Joint Collegiate Council for Oncology/Association of Cancer Physicians 07 August 2008 68.99 KB
Kidney Research UK 07 August 2008 26.83 KB
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: manufacturer submissions (executive summary only)
Bayer 07 August 2008 37.75 KB
Pfizer 07 August 2008 83.02 KB
Pfizer - addendum to submission 07 August 2008 52.04 KB
Roche 07 August 2008 32.37 KB
Wyeth 07 August 2008 73.87 KB
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: expert written personal statements
Chao 07 August 2008 21.63 KB
Hanlon 07 August 2008 21.3 KB
Savage 07 August 2008 38.43 KB
Patient Expert Statement 15 August 2008 36.33 KB

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

Background information

Appendix A: decision paper presented to the Institute's Guidance Executive 30 May 2012 62.34 KB

Appendix A: decision paper presented to the Institute's Guidance Executive 30 May 2012 62.34 KB

Appendix A: provisional matrix of stakeholders 09 March 2012 61.5 KB

Appendix B: proposal paper presented to the Institute's guidance executive 09 March 2012 178.71 KB

NICE issues guidance on the use of other treatment options for renal cancer 06 December 2013 33.1 KB

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal

Roche

Roche: appeals received 13 July 2009 74.34 KB

Roche: initial scrutiny letter 13 July 2009 24.41 KB

Roche: response to scrutiny letter 13 July 2009 46.76 KB

Roche: final scrutiny letter 13 July 2009 14.69 KB

Wyeth

Wyeth: appeals received 13 July 2009 88.98 KB

Wyeth: initial scrutiny letter 13 July 2009 25.11 KB

Wyeth: response to scrutiny letter 13 July 2009 79.46 KB

Wyeth: final scrutiny letter 13 July 2009 17.53 KB

Wyeth: clarification letter 13 July 2009 59.88 KB

Wyeth: response to clarification letter 13 July 2009 13.54 KB

James Whale Fund for Kidney Cancer

James Whale Fund for Kidney Cancer: appeals received 13 July 2009 66.33 KB

James Whale Fund for Kidney Cancer: initial scrutiny letter 13 July 2009 25.64 KB

James Whale Fund for Kidney Cancer: response to scrutiny letter 13 July 2009 104.83 KB

James Whale Fund for Kidney Cancer: final scrutiny letter 13 July 2009 16.36 KB

Rarer Cancers Forum and Macmillan Cancer Support

Rarer Cancers Forum and Macmillan Cancer Support: appeals received 13 July 2009 45.58 KB

Rarer Cancers Forum and Macmillan Cancer Support: initial scrutiny letter 13 July 2009 26.52 KB

Rarer Cancers Forum and Macmillan Cancer Support: response to scrutiny letter 13 July 2009 17.12 KB

Rarer Cancers Forum and Macmillan Cancer Support: final scrutiny letter 13 July 2009 18.21 KB

Renal cell carcinoma: appeal decision 12 October 2009 72.36 KB

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination 22 April 2009 254.2 KB

Response to consultee, commentator and public comments on the first ACD and comments from website consultation 22 April 2009 286.25 KB

Response to consultee, commentator and public comments on the second ACD and comments from website consultation 22 April 2009 440.52 KB

Consultee and commentator comments on the ACD

Bayer 28 April 2009 45.1 KB

Department of Health 28 April 2009 7.81 KB

Macmillan and Rarer Cancers forum 28 April 2009 54.17 KB

NHS Quality Improvement Scotland 28 April 2009 9.85 KB

Roche 28 April 2009 119.13 KB

Royal College of Nursing 28 April 2009 18.83 KB

Wyeth 28 April 2009 122.11 KB

Expert comments on the ACD

David Chao 28 April 2009 11.36 KB

Bill Savage 28 April 2009 28.39 KB

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination 04 February 2009 155.41 KB

Update on renal cell carcinoma drugs 04 February 2009 14.74 KB

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) 10 February 2009 474.99 KB

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report

Consultee and commentator comments on the first ACD

Bayer 04 February 2009 28.97 KB

British Uro-oncology Group (BUG) 04 February 2009 70.35 KB

Cancer Research UK 04 February 2009 39.24 KB

Kidney cancer UK/James Whale fund for kidney cancer 04 February 2009 69.56 KB

Macmillan and Rarer Cancers Forum 04 February 2009 41.94 KB

National Kidney Federation 04 February 2009 26.46 KB

NHS Cambridgeshire 04 February 2009 28.85 KB

NHS Quality Improvement Scotland 04 February 2009 17.43 KB

Novartis 04 February 2009 19.6 KB

Pfizer 04 February 2009 331.17 KB

Royal College of Physicians 04 February 2009 46.17 KB

Roche 04 February 2009 47.57 KB

Welsh Assembly Government 04 February 2009 53.53 KB

Wyeth 04 February 2009 85.38 KB

Wyeth 2 04 February 2009 21.53 KB

External expert comments on the appraisal consultation document

Dr David Chao 04 February 2009 23.55 KB

Patient expert 04 February 2009 17.46 KB

Bill Savage 04 February 2009 19.57 KB

Report to the Appraisal Committee summarising comments (received by letter and email) on the appraisal consultation document - prepared by the Patient and Public Involvement Programme (PPIP) and Enquiry Handling team, September 2008 04 February 2009 1013.89 KB

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic and economic evaluation - addendum to the report submitted on 2 May 2008 - prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter 04 February 2009 155.54 KB

Extra work on bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma - prepared by Decision Support Unit 04 February 2009 133.14 KB

First appraisal consultation document 04 February 2009 232.59 KB

Response from the Assessment Group to comments on the Assessment report 04 February 2009 209.6 KB

Consultee and commentator comments on the extra work consultation